These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 32912157)

  • 1. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
    Belyavskiy E; Ovchinnikov A; Potekhina A; Ageev F; Edelmann F
    BMC Cardiovasc Disord; 2020 Sep; 20(1):408. PubMed ID: 32912157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) Trial.
    Hussain I; Mohammed SF; Forfia PR; Lewis GD; Borlaug BA; Gallup DS; Redfield MM
    Circ Heart Fail; 2016 Apr; 9(4):e002729. PubMed ID: 27072860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure.
    Malhotra R; Dhakal BP; Eisman AS; Pappagianopoulos PP; Dress A; Weiner RB; Baggish AL; Semigran MJ; Lewis GD
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27301469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction.
    Borlaug BA; Lewis GD; McNulty SE; Semigran MJ; LeWinter M; Chen H; Lin G; Deswal A; Margulies KB; Redfield MM
    Circ Heart Fail; 2015 May; 8(3):533-41. PubMed ID: 25782985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
    Hoendermis ES; Liu LC; Hummel YM; van der Meer P; de Boer RA; Berger RM; van Veldhuisen DJ; Voors AA
    Eur Heart J; 2015 Oct; 36(38):2565-73. PubMed ID: 26188003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension.
    Liu LC; Hummel YM; van der Meer P; Berger RM; Damman K; van Veldhuisen DJ; Voors AA; Hoendermis ES
    Eur J Heart Fail; 2017 Jan; 19(1):116-125. PubMed ID: 27873388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
    Redfield MM; Chen HH; Borlaug BA; Semigran MJ; Lee KL; Lewis G; LeWinter MM; Rouleau JL; Bull DA; Mann DL; Deswal A; Stevenson LW; Givertz MM; Ofili EO; O'Connor CM; Felker GM; Goldsmith SR; Bart BA; McNulty SE; Ibarra JC; Lin G; Oh JK; Patel MR; Kim RJ; Tracy RP; Velazquez EJ; Anstrom KJ; Hernandez AF; Mascette AM; Braunwald E;
    JAMA; 2013 Mar; 309(12):1268-77. PubMed ID: 23478662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
    Guazzi M; Vicenzi M; Arena R; Guazzi MD
    Circulation; 2011 Jul; 124(2):164-74. PubMed ID: 21709061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials.
    Hwang IC; Kim YJ; Park JB; Yoon YE; Lee SP; Kim HK; Cho GY; Sohn DW
    BMC Cardiovasc Disord; 2017 Jun; 17(1):150. PubMed ID: 28606099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
    Kramer T; Dumitrescu D; Gerhardt F; Orlova K; Ten Freyhaus H; Hellmich M; Baldus S; Rosenkranz S
    Int J Cardiol; 2019 May; 283():152-158. PubMed ID: 30777406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction.
    Andersen MJ; Hwang SJ; Kane GC; Melenovsky V; Olson TP; Fetterly K; Borlaug BA
    Circ Heart Fail; 2015 May; 8(3):542-50. PubMed ID: 25857307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
    BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial.
    Cooper TJ; Cleland JGF; Guazzi M; Pellicori P; Ben Gal T; Amir O; Al-Mohammad A; Clark AL; McConnachie A; Steine K; Dickstein K
    Eur J Heart Fail; 2022 Jul; 24(7):1239-1248. PubMed ID: 35596935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase inhibitor for heart failure with preserved ejection fraction: A systematic review and meta-analysis.
    Chen Z; Zhao K; Xiao C; He Z; Liu S; Wu X; Shi S; Guo Y
    Saudi Pharm J; 2022 Aug; 30(8):1079-1087. PubMed ID: 36164567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary vascular and right ventricular reserve in patients with normalized resting hemodynamics after pulmonary endarterectomy.
    Claessen G; La Gerche A; Dymarkowski S; Claus P; Delcroix M; Heidbuchel H
    J Am Heart Assoc; 2015 Mar; 4(3):e001602. PubMed ID: 25801760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Beraprost Sodium Combined with Sildenafil and Its Effects on Vascular Endothelial Function and Inflammation in Patients Experiencing Left Heart Failure Complicated with Pulmonary Arterial Hypertension.
    Sun D; Yang W; Wang Z; Gao B
    Med Sci Monit; 2021 Feb; 27():e928413. PubMed ID: 33531453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; McKie PM; Dunlay SM; Stevens SR; Felker GM; Borlaug BA; Chen HH; Tracy RP; Braunwald E; Redfield MM
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28214792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.
    Lindman BR; Dávila-Román VG; Mann DL; McNulty S; Semigran MJ; Lewis GD; de las Fuentes L; Joseph SM; Vader J; Hernandez AF; Redfield MM
    J Am Coll Cardiol; 2014 Aug; 64(6):541-9. PubMed ID: 25104521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RV Contractile Function and its Coupling to Pulmonary Circulation in Heart Failure With Preserved Ejection Fraction: Stratification of Clinical Phenotypes and Outcomes.
    Guazzi M; Dixon D; Labate V; Beussink-Nelson L; Bandera F; Cuttica MJ; Shah SJ
    JACC Cardiovasc Imaging; 2017 Oct; 10(10 Pt B):1211-1221. PubMed ID: 28412423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.
    Zakeri R; Borlaug BA; McNulty SE; Mohammed SF; Lewis GD; Semigran MJ; Deswal A; LeWinter M; Hernandez AF; Braunwald E; Redfield MM
    Circ Heart Fail; 2014 Jan; 7(1):123-30. PubMed ID: 24162898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.